Literature DB >> 12353342

In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia.

Shwu-Jen Liaw1, Lee-Jene Teng, Po-Ren Hsueh, Shen-Wu Ho, Kwen-Tay Luh.   

Abstract

BACKGROUND AND
PURPOSE: Stenotrophomonas maltophilia, a major pathogen causing nosocomial infection, is inherently resistant to multiple antimicrobial agents. Evaluation of the effectiveness of recommended therapeutic options for S. maltophilia infections is crucial, particularly in areas with high antimicrobial resistance in this nosocomial pathogen.
METHODS: The in vitro activities of ceftazidime (CAZ), ticarcillin-clavulanate (TIM), amikacin (AN), ciprofloxacin (CIP), and trimethoprim-sulfamethoxazole (TMP-SMZ) against 102 clinical isolates of S. maltophilia collected from January 1998 to December 1999 at a university hospital were evaluated. The disk diffusion and agar dilution susceptibilities of individual agents against these isolates were determined concomitantly. Errors between results obtained by the two methods were identified based on the guidelines for Acinetobacter species provided by the National Committee for Clinical Laboratory Standards. Activities of three two-drug combinations (AN + CIP, CAZ + CIP, and TIM + TMP-SMZ) against 32 of these isolates were analyzed using the checkerboard synergy test.
RESULTS: Among the agents tested, TMP-SMZ was the most active against S. maltophilia (83.3% susceptible), followed by CIP (63.7%), CAZ (39.2%), TIM (36.2%), and AN (20.5%). Errors (very major and major) between the results obtained by the disk diffusion and agar dilution methods occurred at a high frequency for AN (15% and 3%), CAZ (8% and 6%), and CIP (3% and 3%). Synergy or partial synergy of antimicrobial agent combinations was detected predominantly with CAZ + CIP (81.3%) and TIM + TMP-SMZ (84.4%) but not with AN + CIP (37.5%). No antagonism was detected with any drug combinations.
CONCLUSION: The dilution method is preferable to the disk diffusion method for susceptibility testing of S. maltophilia isolates, particularly for testing with AN, CAZ, and TIM, which have considerable error rates between the results obtained by the two methods. The findings from the synergy test suggest that TIM + TMP-SMZ and CAZ + CIP combinations are the treatments of choice for infections caused by S. maltophilia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12353342

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  6 in total

Review 1.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 2.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

3.  A Combination of Trimethoprim-sulfamethoxazole and Ceftazidime Showed Good In Vitro Activity against Stenotrophomonas maltophilia.

Authors:  Nabilah Ismail; Zarifah Zam; Siti Asma Hassan; Zaidah Abdul Rahman
Journal:  Malays J Med Sci       Date:  2017-04-14

4.  Antibiogram of Stenotrophomonas maltophilia Isolated From Nkonkobe Municipality, Eastern Cape Province, South Africa.

Authors:  Anthony Ayodeji Adegoke; Anthony I Okoh
Journal:  Jundishapur J Microbiol       Date:  2014-12-10       Impact factor: 0.747

5.  Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates.

Authors:  Hae-Sun Chung; Seong Geun Hong; Young Ree Kim; Kyeong Seob Shin; Dong Hee Whang; Jee Young Ahn; Yeon-Joon Park; Young Uh; Chulhun L Chang; Jong Hee Shin; Hye Soo Lee; Kyungwon Lee; Yunsop Chong
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

Review 6.  Infections Caused by Stenotrophomonas maltophilia in Recipients of Hematopoietic Stem Cell Transplantation.

Authors:  Khalid Ahmed Al-Anazi; Asma M Al-Jasser
Journal:  Front Oncol       Date:  2014-08-25       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.